Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Spine|November 9, 2019
Percutaneous Transforaminal Endoscopic Discectomy Versus Microendoscopic Discectomy for Lumbar Disc Herniation: Two-Year Results of a Randomized Controlled TrialZihao Chen, Liangming Zhang, Jianwen Dong, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 20, 2021
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III StudyShukui Qin, Jin Li, Yuxian Bai, et al.
Journal of Vascular and Interventional Radiology : JVIR|March 27, 2021
Computed Tomography‒Guided Microwave Ablation Combined with Osteoplasty for the Treatment of Bone Metastases: A Multicenter Clinical StudyXusheng Zhang, Xin Ye, Kaixian Zhang, et al.
BMC Medicine|January 8, 2023
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa studyYuankai Shi, Jianying Zhou, Yanqiu Zhao, et al.
Cell Reports|August 21, 2025
Cross-species single-cell transcriptomic atlas of retinal photoreceptors reveals molecular signatures underlying color vision adaptationZhibin Li, Chengkai Yan, Yubao Lu, et al.
Cell Reports|June 8, 2023
Distinct myeloid population phenotypes dependent on TREM2 expression levels shape the pathology of traumatic versus demyelinating CNS disordersHan Gao, Jiawei Di, Bettina Hjelm Clausen, et al.
Breast (Edinburgh, Scotland)|February 15, 2025
Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trialBinghe Xu, Qingyuan Zhang, Tao Sun, et al.
Nucleic Acids Research|November 6, 2023
SCAN: Spatiotemporal Cloud Atlas for Neural cellsYushan Deng, Yubao Lu, Mengrou Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2022
Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion StudyYuankai Shi, Yanqiu Zhao, Sheng Yang, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Pageof 12